Special Issue

Carbapenem Resistant Pathogens: Epidemiology, Treatment and Prevention

Message from the Guest Editor

Carbapenem resistance is a wide umbrella definition encompassing both nonfermenters (e.g., *A. baumannii*, *P. aeruginosa*) and fermenters (e.g., Enterobacterales) but comprises distinct resistance mechanisms and molecular epidemiology that varies regionally. There is a need for global investigations into emerging mechanisms and epidemiology underlying these evasive organisms and into the effectiveness of treatments that can guide clinicians and public health agencies to efficiently diagnose, treat, and prevent the spread of these organisms. Topics welcome for submission to this Special Issue include, but are not limited to:

- Emerging mechanisms and features underlying non-carbapenemase-producing, carbapenem-resistant organisms;
- Comparative infection prevention measures targeting carbapenem-resistant organisms;
- Therapeutic approaches to non-carbapenemase-producing, carbapenem-resistant organisms;
- Impact of COVID-19 on regional variation in antimicrobial utilization and infection prevention measures with shifts in epidemiology of carbapenem-resistant organisms.

Keywords: carbapenem resistance; epidemiology; Gram-negative; carbapenemase; non-carbapenemase

Guest Editor

Dr. Grace C. Lee

College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA

Deadline for manuscript submissions

closed (15 September 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/144753

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI